시장보고서

상품코드

1514928

트라코마 치료 시장 : 치료별, 투여 형태별, 약제 클래스별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

Trachoma Treatment Market, By Treatment, By Mode of Administration, By Drug Class, By End-Users, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 06월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 375 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

트라코마 치료 시장 규모는 2023년 5억 4,465만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 5.8%로 확대

트라코마 치료 시장 - 시장 역학

지속적인 정부 지원은 트라코마 치료 시장의 성장을 가속

지속적인 정부 지원은 트라코마 치료 시장의 성장을 가속하는데 매우 중요한 역할을 합니다. 세계 각국의 다양한 정부가 세계보건기구(WHO) 및 비정부기구(NGO) 등의 조직과 협력하여 트라코마에 효과적으로 대처하기 위한 종합적인 프로그램을 실시했습니다. 예를 들어, WHO의 SAFE 전략(수술, 항생제, 얼굴 청결, 환경 개선)은 각국 정부로부터 큰 지지와 자금 지원을 받고 있으며, 항생제 배포, 수술 개입 제공, 유행 지역의 위생 습관의 촉진을 지원합니다. WHO의 SAFE 전략으로 2002년 이후 트라코마의 유병률은 91% 감소했습니다. 또한 정부 이니셔티브에는 전용 건강 관리 인프라 구축, 의료 전문가 교육, 질병 유행 및 치료 성과를 모니터링하는 지속적인 감시가 포함됩니다. 이러한 정부의 지속적인 지원은 의식 향상, 치료 접근성 확보, 궁극적으로 세계 트라코마의 부담 경감에 도움이 됩니다.

트라코마 치료 시장 - 주요 인사이트

우리의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 5.8%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

치료 세분화에 근거하여, 투약이 2023년에 최대 시장 점유율을 나타낼 것으로 예측됩니다.

투여 형태별로 경구 투여는 2023년의 주요 유형이었습니다.

약물 등급별로 2023년에는 항생제가 주요 유형이었습니다.

지역별로 북미는 2023년 주요 수익원이었습니다.

트라코마 치료 시장 - 세분화 분석 :

세계의 트라코마 치료 시장은 치료법, 투여 방법, 약물 등급별, 최종 사용자별, 지역별로 구분됩니다.

시장은 치료에 따라 두 가지 범주로 나뉩니다. 약물 요법과 수술 요법입니다. 약물 요법은 트라코마 치료 시장의 주요 치료 수단으로, 아지트로마이신 및 테트라사이클린과 같은 항생제가 박테리아 감염과 싸우는 데 널리 사용됩니다. 수술은 주로 흉터와 속눈썹 난생을 동반한 진행된 사례를 대상으로 하며, 시력 장애에 대처하고 질병의 진행 방지에 있어서 소규모이면서 중요한 부문을 차지하고 있습니다.

시장은 투여 방법에 따라 네 가지 범주로 나뉩니다: 경구 투여는 트라코마 치료 시장을 독점하고 있으며, 박테리아 감염과 싸우는 항생제의 간편하고 광범위한 투여가 가능합니다. 국소 치료도 보급되어 있으며, 특히 안구의 염증이나 불쾌감 등의 증상에 대응하고 있습니다. 주사 요법은 그다지 흔하지 않으며 주로 중증 사례와 수술적 개입과의 병용으로 제한됩니다.

트라코마 치료 시장 - 지리적 통찰

사하라 이남의 아프리카, 중동, 아시아의 일부 유행 지역에서는 트라코마의 유병률이 높고 치료 솔루션에 대한 수요가 높아지고 있습니다. 이 지역의 정부와 국제기구는 Global Trachoma Mapping Project와 Queen Elizabeth Diamond Jubilee Trust와 같은 이니셔티브의 자금 지원을 통해 개입 프로그램을 적극적으로 시행하고 있습니다. 또한 북미와 유럽과 같은 의료 인프라가 확립된 선진지역은 연구자금과 의약품 개발 지원을 통해 시장개척에 기여하고 있습니다.

트라코마 치료 시장 - 경쟁 구도:

화이자, 노바티스, 머크와 같은 제약 회사는 트라코마 치료를 위해 아지트로마이신 및 테트라사이클린과 같은 항생제를 제공하며 의약품 개발 및 유통에 중요한 역할을 하고 있습니다. 또한 국제 트라코마 이니셔티브(ITI) 및 카터 센터와 같은 비영리 단체는 각국 정부 및 제약 회사와 협력하여 트라코마 감염 지역에서 약물을 제공하고 위생 프로그램을 실시하고 수술을 수행합니다. 또한 세계보건기구(WHO)와 각국의 보건부 등 정부 기관도 트라코마의 제압·박멸을 위한 정책의 책정, 자금의 제공, 대처의 조정 등에 크게 공헌하고 있습니다. 제약회사, 비영리단체, 정부의 이러한 협력적 접근은 트라코마에 대처하기 위한 협력적인 노력을 강조하여 시장 경쟁 구도를 형성하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 트라코마 치료 업계

경쟁 대시보드
기업 프로파일
- AbbVie Inc.
- Allergan plc(now part of AbbVie)
- AstraZeneca plc
- Bausch Health Companies Inc.
- Bayer AG
- Cipla Limited
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Merck &Co., Inc.
- Mylan NV(now part of Viatris Inc.)
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Santen Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Others

제13장 애널리스트의 전방위 전망

JHS 24.07.26

REPORT HIGHLIGHT

Trachoma Treatment Market size was valued at USD 544.65 million in 2023, expanding at a CAGR of 5.8% from 2024 to 2032.

The Trachoma Treatment Market comprises therapies and interventions aimed at combating trachoma, an infectious eye disease caused by the bacterium Chlamydia trachomatis, and is poised for growth driven by initiatives like the WHO's SAFE strategy (Surgery, Antibiotics, Facial cleanliness, and Environmental improvements), increasing awareness campaigns, and enhanced access to healthcare services in endemic regions. However, challenges such as limited access to healthcare in rural areas, inadequate infrastructure, and the high cost of treatment pose restraints. Market opportunities lie in the development of innovative treatments, strategic partnerships with NGOs and government organizations, and the implementation of preventative measures to reduce disease prevalence and improve overall eye health in affected populations.

Trachoma Treatment Market- Market Dynamics

Continuous Government Support Propel Growth in the Trachoma Treatment Market

Continuous government support is playing a pivotal role in propelling the growth of the Trachoma Treatment Market. Various governments worldwide, in collaboration with organizations like the World Health Organization (WHO) and non-governmental organizations (NGOs), are implementing comprehensive programs to tackle trachoma effectively. For instance, the WHO's SAFE strategy (Surgery, Antibiotics, Facial cleanliness, and Environmental improvements) has received significant endorsement and funding from governments, aiding in the distribution of antibiotics, provision of surgical interventions, and promotion of hygiene practices in endemic regions. The WHO's SAFE strategy has reduced trachoma prevalence by 91% since 2002. Additionally, government initiatives include the establishment of dedicated healthcare infrastructure, training of healthcare professionals, and ongoing surveillance to monitor disease prevalence and treatment outcomes. This sustained governmental support is instrumental in driving awareness, ensuring access to treatment, and ultimately reducing the burden of trachoma worldwide.

Trachoma Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.8% over the forecast period (2024-2032)

Based on Treatment segmentation, Medication was predicted to show maximum market share in the year 2023

Based on Mode of Administration segmentation, Oral administration was the leading type in 2023

Based on Drug Class segmentation, Antibiotics was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Trachoma Treatment Market- Segmentation Analysis:

The Global Trachoma Treatment Market is segmented based on Treatment, Mode of Administration, Drug Class, End-Users, and Region.

The market is divided into two categories based on Treatment: Medication, and Surgery. Medication is the predominant treatment modality in the Trachoma Treatment Market, with antibiotics like azithromycin and tetracycline being widely used to combat bacterial infection. Surgery, primarily targeting advanced cases with scarring and trichiasis, represents a smaller yet crucial segment in addressing vision impairment and preventing disease progression.

The market is divided into four categories based on the Mode of Administration: Oral administration dominates the Trachoma Treatment Market, facilitating easy and widespread delivery of antibiotics to combat bacterial infection. Topical treatments are also prevalent, particularly for addressing symptoms like ocular inflammation and discomfort. Injectable therapies are less common, primarily reserved for severe cases or in conjunction with surgical interventions.

Trachoma Treatment Market- Geographical Insights

Endemic areas in sub-Saharan Africa, the Middle East, and parts of Asia exhibit a higher prevalence of trachoma, driving demand for treatment solutions. Governments and international organizations in these regions are actively implementing intervention programs, supported by funding from initiatives like the Global Trachoma Mapping Project and the Queen Elizabeth Diamond Jubilee Trust. In addition, developed regions with established healthcare infrastructure, such as North America and Europe, contribute to market growth through research funding and support for drug development.

Trachoma Treatment Market- Competitive Landscape:

Pharmaceutical companies such as Pfizer Inc., Novartis AG, and Merck & Co., Inc., play a crucial role in drug development and distribution, offering antibiotics like azithromycin and tetracycline for trachoma treatment. Additionally, nonprofit organizations such as the International Trachoma Initiative (ITI) and the Carter Center work in collaboration with governments and pharmaceutical companies to provide medication, implement hygiene programs, and conduct surgeries in affected regions. Governmental organizations like the World Health Organization (WHO) and national health ministries also contribute significantly by formulating policies, providing funding, and coordinating efforts to control and eliminate trachoma. This collaborative approach among pharmaceutical companies, nonprofit organizations, and governments underscores the concerted effort to address trachoma, thereby shaping the competitive landscape of the market.

Recent Developments:

In June 2022, Pfizer pledged to prolong its antibiotic donation initiative until 2025, ensuring the continued availability of Zithromax to aid endemic countries in meeting their targets for trachoma elimination. This commitment strengthens Pfizer's longstanding partnership with ITI and the global health community.

In July 2023, Vision Spring, Live Well, and the Council of Churches Zambia unveiled a new initiative in Zambia. The program is expected to cater to around 75% of participants requiring vision correction, encompassing treatments for conditions such as trachoma and cataracts.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TRACHOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.

Allergan plc (now part of AbbVie)

AstraZeneca plc

Bausch Health Companies Inc.

Bayer AG

Cipla Limited

F. Hoffmann-La Roche AG

GlaxoSmithKline plc

Merck & Co., Inc.

Mylan N.V. (now part of Viatris Inc.)

Novartis AG

Pfizer Inc.

Sanofi S.A.

Santen Pharmaceutical Co., Ltd.

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Others

GLOBAL TRACHOMA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

Medication
Surgery

GLOBAL TRACHOMA TREATMENT MARKET, BY MODE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Topical
Injectable
Surgical

GLOBAL TRACHOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Macrolides
Tetracycline
Ophthalmic anti-infective
Sulfonamides

GLOBAL TRACHOMA TREATMENT MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032

Hospitals
Specialty Clinics
Homecare
Others

GLOBAL TRACHOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Trachoma Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Trachoma Treatment Market Snippet by Treatment
- 2.1.2. Trachoma Treatment Market Snippet by Mode of Administration
- 2.1.3. Trachoma Treatment Market Snippet by Drug Class
- 2.1.4. Trachoma Treatment Market Snippet by End-Users
- 2.1.5. Trachoma Treatment Market Snippet by Country
- 2.1.6. Trachoma Treatment Market Snippet by Region
2.2. Competitive Insights

3. Trachoma Treatment Key Market Trends

3.1. Trachoma Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Trachoma Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Trachoma Treatment Market Opportunities
3.4. Trachoma Treatment Market Future Trends

4. Trachoma Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Trachoma Treatment Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Trachoma Treatment Market Landscape

6.1. Trachoma Treatment Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Trachoma Treatment Market - By Treatment

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
- 7.1.2. Medication
- 7.1.3. Surgery

8. Trachoma Treatment Market - By Mode of Administration

8.1. Overview
- 8.1.1. Segment Share Analysis, By Mode of Administration, 2023 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Topical
- 8.1.4. Injectable
- 8.1.5. Surgical

9. Trachoma Treatment Market - By Drug Class

9.1. Overview
- 9.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 9.1.2. Macrolides
- 9.1.3. Tetracycline
- 9.1.4. Ophthalmic anti-infective
- 9.1.5. Sulfonamides

10. Trachoma Treatment Market - By End-Users

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-Users, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Specialty Clinics
- 10.1.4. Homecare
- 10.1.5. Others

11. Trachoma Treatment Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Trachoma Treatment Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Trachoma Treatment Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Trachoma Treatment Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Trachoma Treatment Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Trachoma Treatment Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Mode of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Trachoma Treatment Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. AbbVie Inc.
- 12.2.2. Allergan plc (now part of AbbVie)
- 12.2.3. AstraZeneca plc
- 12.2.4. Bausch Health Companies Inc.
- 12.2.5. Bayer AG
- 12.2.6. Cipla Limited
- 12.2.7. F. Hoffmann-La Roche AG
- 12.2.8. GlaxoSmithKline plc
- 12.2.9. Merck & Co., Inc.
- 12.2.10. Mylan N.V. (now part of Viatris Inc.)
- 12.2.11. Novartis AG
- 12.2.12. Pfizer Inc.
- 12.2.13. Sanofi S.A.
- 12.2.14. Santen Pharmaceutical Co., Ltd.
- 12.2.15. Sun Pharmaceutical Industries Ltd.
- 12.2.16. Teva Pharmaceutical Industries Ltd.
- 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us